Search results for "Coma"

showing 10 items of 1084 documents

A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma.

2021

11505 Background: AL3818 (Catequentinib, Anlotinib) is a novel, orally administered, small molecule tyrosine kinase inhibitor. The primary objective of this Phase 3 study is to evaluate the efficacy of AL3818 monotherapy in patients (pts) with synovial sarcoma (SS) comparing with dacarbazine in randomization setting. Methods: Patients with a diagnosis of synovial sarcoma requiring second line or further line treatment were eligible for enrollment. The regimen was a 21-day cycle with oral AL3818 administered on 14 days on and 7 days off. This phase 3 trial is randomized in 2:1 ratio of AL3818 comparing to dacarbazine with option of crossover after PD of dacarbazine treatment. Progression fr…

Cancer Researchbusiness.industrymedicine.drug_classPhases of clinical researchmedicine.diseaseSmall moleculeSynovial sarcomaTyrosine-kinase inhibitorOncologyPhase (matter)Cancer researchMedicineAnlotinib HydrochloridebusinessJournal of Clinical Oncology
researchProduct

823: 3-deazaneplanocin A (DZNep), an inhibitor of histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells

2014

Cancer Researchchemistry.chemical_compoundOncologyChemistryApoptosisHistone methyltransferaseEZH2medicineCancer research3-Deazaneplanocin ACell migrationChondrosarcomamedicine.diseaseEuropean Journal of Cancer
researchProduct

Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors

2022

Gastrointestinal Stromal Tumors (GISTs) represent a paradigmatic model of oncogene addiction. Despite the well-known impact of the mutational status on clinical outcomes, we need to expand our knowledge to other factors that influence behavior heterogeneity in GIST patients. A growing body of studies has revealed that the tumor microenvironment (TME), mostly populated by tumor-associated macrophages (TAMs) and lymphocytes (TILs), and stromal differentiation (SD) have a significant impact on prognosis and response to treatment. Interestingly, even though the current knowledge of the role of immune response in this setting is still limited, recent pre-clinical and clinical data have highlight…

Cancer Researchimmune systemOncologytarget therapytumor microenvironmentimmunotherapyimmune checkpointssarcomasGIST
researchProduct

Fetal calf serum and retinoic acid affect proliferation and terminal differentiation of a rat rhabdomyosarcoma cell line (BA-HAN-1C)

1989

We report on the establishment of a model for differentiation induction in sarcomas, using the clonal rhabdomyosarcoma cell line BA-HAN-1C. This rhabdomyosarcoma cell line is composed of morphologically undifferentiated mononuclear stem cells, some of which spontaneously fuse to form terminally differentiated multinuclear myotube-like giant cells. The deprivation of fetal calf serum (FCS) or the exposure to retinoic acid, respectively, resulted in a significant inhibition of proliferation (P less than 0.001) and a marked increase in cellular differentiation as shown by a significant increase in the number of myotube-like giant cells (P less than 0.001) and in the creatine kinase activity (P…

Cancer Researchmedicine.medical_specialtyCell divisionCellular differentiationRetinoic acidTretinoinBiologyCell Linechemistry.chemical_compoundTretinoinInternal medicineRhabdomyosarcomaTumor Cells CulturedmedicineAnimalsCell DifferentiationFetal BloodMolecular biologyRatsP19 cellEndocrinologyOncologychemistryGiant cellCell cultureCattleStem cellCell DivisionResearch Articlemedicine.drugBritish Journal of Cancer
researchProduct

Tumor response assessment by Choi criteria in localized high-risk soft tissue sarcoma (STS) treated with chemotherapy (CT): Update at 10-year follow-…

2016

11044Background: We already reported (Cancer 2012;118:5857) on better correlation of Choi criteria (Choi) than RECIST with the outcome of pts affected by high-risk STS entering a multicentric Itali...

Cancer Researchmedicine.medical_specialtyChemotherapybusiness.industry10 year follow upSoft tissue sarcomamedicine.medical_treatmentCancerExploratory analysismedicine.diseaseTumor response030218 nuclear medicine & medical imagingSurgery03 medical and health sciences0302 clinical medicineOncologyChoi Criteria030220 oncology & carcinogenesismedicineRadiologybusinessJournal of Clinical Oncology
researchProduct

Multidisciplinary treatment of primary Ewing's sarcoma of bone.A 6-year experience of a European cooperative trial

1988

The German Society of Pediatric Oncology in 1981 initiated the Cooperative Ewing's Sarcoma Study (CESS 81) using a four-drug combination of chemotherapy prior to definitive local control with surgery and/or radiation. From January 1, 1981 until February 28, 1985, 93 patients were registered at the trial office from 54 participating institutions in West Germany, Austria, Switzerland, and the Netherlands. On February 1, 1987, 54 of 93 patients were disease-free. Using the Kaplan-Meier life table analysis, the estimated disease-free survival (DFS) rate was 60% at 36 months and 55% at 69 months. The median period of observation was 29 months, ranging from 22 months to 69 months. Twenty-one of 9…

Cancer Researchmedicine.medical_specialtyChemotherapybusiness.industryProportional hazards modelmedicine.medical_treatmentEwing's sarcomaLocal failuremedicine.diseaseRadiation planningSurgeryOncologyLife tablemedicineIn patientSarcomabusinessCancer
researchProduct

Einflu� einer Hyperglyk�mie auf die Sauerstoff- und Glucoseaufnahme von Implantationstumoren (DS-Carcinosarkom) in vivo

1972

Um den Einflus erhohter arterieller Glucosekonzentrationen auf die Glucose- und Sauerstoffaufnahme von Tumorgewebe unter in vivo-Bedingungen zu bestimmen, wurden Untersuchungen an gewebsisolierten Implantationstumoren von Ratten (DS-Carcinosarkom) durchgefuhrt.

Cancer Researchmedicine.medical_specialtyHematologyGlucose uptakechemistry.chemical_elementGeneral MedicinePharmacologymedicine.diseaseOxygenOncologychemistryIn vivoInternal medicineCarcinosarcomamedicineZeitschrift f�r Krebsforschung und Klinische Onkologie
researchProduct

Trabectedin-Related Liver Toxicity in Soft Tissue Sarcoma Patients: Always a Good Reason to Discontinue the Treatment?

2014

ABSTRACT Aim: A transient increase in liver enzymes is a well described side effect developed by almost 40% of soft tissue sarcoma (STS) patients treated with trabectedin, often leading to treatment delays or discontinuation. We retrospectively analysed the correlation between trabectedin-related liver toxicity and treatment outcome. Methods: Data from a total of 113 patients receiving trabectedin administered at the dose of 1.5 mg/m2 iv 24 hours in 3 reference centers were evaluated. This exploratory analysis was performed to assess the impact of liver toxicity (grade 3-4 AST and ALT increases) on the trabectedin efficacy and outcome in STS patients. All the patients included had metastati…

Cancer Researchmedicine.medical_specialtyLiver toxicityAnthracyclineSide effectPopulationLiposarcomaGastroenterologyInternal medicinemedicineeducationTrabectedineducation.field_of_studybusiness.industrySoft tissue sarcomaHazard ratioHematologymedicine.diseaseSynovial sarcomaDiscontinuationSurgeryOncologyPremedicationSarcomabusinessmedicine.drugAnnals of Oncology
researchProduct

Advanced epithelioid haemangioendotelioma: Fever, pain, and pleural effusion predict a worse outcome.

2019

e22540 Background: Epithelioid hemangioendothelioma (EHE) is an exceedingly rare soft tissue sarcoma subtype. EHE often presents as a multifocal/ multivisceral disease and its clinical behavior is highly unpredictable from indolent to very aggressive forms. A common choice in advanced patients is a close, active surveillance (AS), considering a treatment only in case of disease progression. Our retrospective study aimed to identify clinical features associated with a more aggressive behavior. Methods: Patients affected by advanced EHE treated in 6 centers of the Italian Rare Cancer Network were retrospectively reviewed. Diagnosis was confirmed by a sarcoma expert pathologist and molecular …

Cancer Researchmedicine.medical_specialtyOncologyPleural effusionbusiness.industrySoft tissue sarcomamedicineRadiologymedicine.diseasebusinessEpithelioid hemangioendotheliomaJournal of Clinical Oncology
researchProduct

Cerebral metastases of an endometrial stromal sarcoma: report of the first case.

2012

Endometrial stromal sarcomas (ESSs) of the uterus are rare gynecological malignancies. Common locations of distant metastases are vagina, vulva, lung, mediastinum, abdomen, bones and ovaries.We present the case of a 69-year-old woman with a Federation of Gynecology and Obstetrics (FIGO) IIb (classification 2009) ESS of the uterus of high-grade malignancy. Initially, a hysterectomy Piver II and total colpectomy were performed, followed by pelvic field irradiation. 8 months later, the patient suffered seizures and hemiparesis. A computed tomography (CT) scan revealed cerebral metastases, and irradiation of the brain was initiated. After completion of the staging examinations, additional metas…

Cancer Researchmedicine.medical_specialtyPathologyStromal cellSarcoma Endometrial StromalUterusVulvamedicineHumansAgedEndometrial stromal sarcomaLungUterine sarcomaurogenital systembusiness.industryBrain NeoplasmsHematologyGeneral Medicinemedicine.diseaseEndometrial Neoplasmsmedicine.anatomical_structureTreatment OutcomeOncologyVaginaFemaleRadiologybusinessOnkologie
researchProduct